← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Baker Bros. Advisors (GP) LLC
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001580575
Purchase history
- Companies traded
- 8
- Purchases · 12M
- 7
- Purchases · 24M
- 14
- Average purchase
- $38.5M
- Median purchase
- $26.9M
- Gross purchase value
- $538.7M
Companies: BICYCLE THERAPEUTICS PLC | Celcuity Inc. | Entrada Therapeutics, Inc. | Immunocore Holdings plc | KALA BIO, Inc. | Kodiak Sciences Inc. | Kymera Therapeutics, Inc. | MADRIGAL PHARMACEUTICALS, INC.
14 SEC accession(s) · 14 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-09-30 | Kodiak Sciences Inc. | KOD | Director | 10% Owner | $35.0M | Open filing |
| 2026-09-30 | Kodiak Sciences Inc. | KOD | Director | 10% Owner | $58.6M | Open filing |
| 2026-09-30 | Kodiak Sciences Inc. | KOD | Director | 10% Owner | $63.4M | Open filing |
| 2025-12-19 | Kodiak Sciences Inc. | KOD | Director | 10% Owner | $60.0M | Open filing |
| 2025-12-11 | Kymera Therapeutics, Inc. | KYMR | Director | 10% Owner | $172.5M | Open filing |
| 2025-11-24 | Entrada Therapeutics, Inc. | TRDA | 10% Owner | $261.8K | Open filing |
| 2025-11-12 | Entrada Therapeutics, Inc. | TRDA | 10% Owner | $1.4M | Open filing |
| 2025-09-10 | Celcuity Inc. | CELC | 10% Owner | $9.6M | Open filing |
| 2025-08-20 | MADRIGAL PHARMACEUTICALS, INC. | MDGL | Director | $25.0M | Open filing |
| 2025-08-20 | MADRIGAL PHARMACEUTICALS, INC. | MDGL | Director | $36.9M | Open filing |
| 2025-06-30 | Kymera Therapeutics, Inc. | KYMR | Director | $28.8M | Open filing |
| 2025-03-19 | Immunocore Holdings plc | IMCR | Director | $24.0M | Open filing |
| 2024-12-31 | KALA BIO, Inc. | KALA | 10% Owner | $2.0M | Open filing |
| 2024-12-17 | BICYCLE THERAPEUTICS PLC | BCYC | Director | 10% Owner | $21.2M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 5Developing | 35.7% (5/14) | 20.0% (1/5) | -5.8% | -2.1% | -5.8% |
| 20D | 2Small Sample | 18.2% (2/11) | 50.0% (1/2) | -4.5% | -4.5% | -11.1% |
| 60D | 2Small Sample | 18.2% (2/11) | 0.0% (0/2) | -19.8% | -19.8% | -29.9% |
| 120D | 2Small Sample | 18.2% (2/11) | 50.0% (1/2) | -11.7% | -11.7% | -43.2% |
Research patterns
- First purchase in 12M
- 2/8
- Large purchase ≥ $100k
- 14/14
- Cluster buying · 15D
- 14/14
- Buying the dip
- 1/5
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.